Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Public ClinicalTrials.gov record NCT05084638. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study also assesses changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if there are similarities between the groups after the patients with MS undergo treatment with ofatumumab.
Study identification
- NCT ID
- NCT05084638
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 35 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2022 (Actual)
- Primary completion
- Feb 4, 2025 (Actual)
- Completion
- Feb 11, 2026 (Actual)
- Last update posted
- Feb 27, 2026
2022 – 2026
United States locations
- U.S. sites
- 35
- U.S. states
- 21
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| MD First Research | Chandler | Arizona | 85226 | — |
| Barrow Neurological Clinics at St Josephs Hospital and MC | Phoenix | Arizona | 85013 | — |
| Arizona Neuroscience Research LLC | Phoenix | Arizona | 85032 | — |
| Keck School of Medicine | Los Angeles | California | 90033 | — |
| Lundquist Inst BioMed at Harbor | Torrance | California | 90509-2910 | — |
| Regina Berkovich MD PhD Inc | West Hollywood | California | 90048 | — |
| UC Health Neuroscience Ctr | Aurora | Colorado | 80045 | — |
| MedStar Health | Washington D.C. | District of Columbia | 20007 | — |
| Neurology of Central FL Res Ctr | Altamonte Springs | Florida | 32714 | — |
| First Choice Neurology | Boca Raton | Florida | 33486 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Neurology Associates PA | Maitland | Florida | 32751 | — |
| Orlando Health Clinical Trials | Orlando | Florida | 32806 | — |
| Emerald Coast Neurology | Pensacola | Florida | 32514 | — |
| Tallahassee Neurological Clinic | Tallahassee | Florida | 32308 | — |
| University Of South Florida | Tampa | Florida | 33612 | — |
| Shepherd Center | Atlanta | Georgia | 30309 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| University of Massachusetts Medical School | Worcester | Massachusetts | 01655 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202-2689 | — |
| Renown Institute for Neurosciences | Reno | Nevada | 89521 | — |
| Neuroscience Institute at Hackensack | Hackensack | New Jersey | 07601 | — |
| University of New Mexico | Albuquerque | New Mexico | 87131-0001 | — |
| Velocity Clinical Research | Raleigh | North Carolina | 27607 | — |
| Neurology Diagnostics Inc | Dayton | Ohio | 45408 | — |
| Multiple Sclerosis Center of Excellence of OMRF | Oklahoma City | Oklahoma | 73104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107-5098 | — |
| Sibyl Wray MD Neurology PC | Knoxville | Tennessee | 37922 | — |
| Univ of Texas Southwest Med Center | Dallas | Texas | 75390-9034 | — |
| UT Health Science Center | Houston | Texas | 77030 | — |
| Lonestar Neurology of San Antonio | San Antonio | Texas | 78258 | — |
| Evergreen Health Multiple Sclerosis Center | Kirkland | Washington | 98034 | — |
| MultiCare Neuroscience Center of Washington | Tacoma | Washington | 98405 | — |
| West Virginia University Hospital | Morgantown | West Virginia | 26506 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05084638, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05084638 live on ClinicalTrials.gov.